Compare Alcon AG (ALC) vs Strategy Inc. (MSTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Strategy Inc. — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Strategy Inc. trades at $93.95 (market cap $34.83B). The key difference: Alcon AG and Strategy Inc. are close in size by market cap, and Alcon AG pays a 0.54% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals.
| ALC | MSTR | |
|---|---|---|
Market Cap | $32.69B | $34.83B |
Sector | Health | Technology |
52-Week High | $92.22 | $455.90 |
52-Week Low | $62.02 | $82.31 |
Enterprise Value | $36.28B | $49.87B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
MSTR stock trades at $97.36, down 3.38% on the day, with a bearish technical signal. The company reported a net loss of $3.85 billion in 2025, with a negative net income margin of -806.35%. Recent news highlights a strategic shift, including a $216 million Bitcoin sale to support preferred stock obligations, marking a departure from its previous 'never sell' stance. Analyst consensus remains largely positive with a $253 price target, but fundamental metrics show significant strain from persistent losses.
The outlook is clouded by deep profitability challenges and high volatility linked to digital asset holdings. Investment opportunity hinges on successful execution of the new capital management framework, but risks include further Bitcoin price declines and inability to achieve sustainable earnings. The stock's trajectory will depend heavily on balancing treasury management with core business performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
